Skip to main content

Global Vaccines Market Size [2021-2028] | to Reach USD 104.87 Billion and Exhibit a Stellar CAGR of 10.7%

Written by Customer Service on . Posted in Mergers And Acquisitions.

Vaccines Market Key Players Studied in this Report Are GlaxoSmithKline plc. (Brentford, United Kingdom), Sanofi (Paris, France), Pfizer Inc. (New York, United States), Merck & Co., Inc. (New Jersey, United States), Novartis AG (Basel, Switzerland), Emergent BioSolutions, Inc. (Maryland, United States), CSL Limited (Melbourne, Australia), Inovio Pharmaceuticals, Inc. (Pennsylvania, United States), Bavarian Nordic (Denmark), Mitsubishi Tanabe Pharma Corporation (Osaka, Japan), Other Prominent Players.

Pune, India, Dec. 07, 2021 (GLOBE NEWSWIRE) — According to the report by Fortune Business Insights, the global Vaccines market size was USD 46.88 billion in 2019 and is projected to reach USD 104.87 billion by 2027, exhibiting a CAGR of 10.7% during the forecast period. ; Rising Demand for Cost-Effective Immunization Therapies to Aid Expansion.


Vaccines Market Report Projection & Coverage:

Report Coverage Details
Forecast Period 2020 to 2027
Forecast Period 2020 to 2027 CAGR 10.7 %
2027 Value Projection USD 104.87 billion
Base Year 2019
Market Size in 2019 USD 46.88 billion
Historical Data for 2016-2018
No. of Pages 156
Segments covered Type, Route of Administration, Disease Indication, Age Group, Distribution Channel, And Region
Growth Drivers Alliances between Raw Material Suppliers and Market Players to Boost Growth
Strong Supply Backed Up by Robust R&D to Drive the Market


Request a Sample Copy of the Research Report: https://www.fortunebusinessinsights.com/enquiry/request-sample-pdf/vaccines-market-101769


Strong Demand for Pocket-friendly Immunization to Boost Growth

The increasing supply of various products to cater to the need of patients will have a positive influence on the market. The surge in unmet needs along with the global aim to eradicate endemic diseases will encourage the development of vaccines. The united focus of pharmaceutical companies, government foundations, international organizations, and hospitals towards cost-effective vaccines and immunization therapies for people around the world. The active government scrutiny for vaccines at a minimum cost or no cost for every individual will further incite market development in the forthcoming years. For instance, the pneumococcal conjugate vaccine was rolled out by the Universal Immunization Programme (UPI) to 21 lakh children in Himachal Pradesh and parts of Bihar in India. The increasing R&D investment by companies for novel products will further escalate market demand, which, in turn, will bode well for the market.


Click here to get the short-term and long-term impacts of COVID-19 on this Market. Please visit: https://www.fortunebusinessinsights.com/industry-reports/vaccines-market-101769


Low Adoption of Vaccines Amid COVID-19

The postponement of immunization campaigns and reduction in the vaccination rate during pandemic has produced major concerns. According to the GAVI, the ceasing of immunizations will result in a lack of vaccination for 13.5 million people from the least developed countries. The decline in pneumococcal vaccine supply will further limit market expansion during coronavirus pandemic. The lower adoption of vaccines in lower- and middle-income nations will subsequently dampen the growth of the market. However, the potential pipeline drugs for coronavirus is expected to contribute enormously to the growth of the market. For Pfizer, Johnson and Johnson, and other players are running clinical trials for potential candidates, which will soon be released after regulatory approvals.


Quick Buy –  Vaccines Market Research Report: https://www.fortunebusinessinsights.com/checkout-page/101769


Presence of Eminent Manufacturers to Influence Growth in North America

The market in North America generated a revenue of USD 24.88 billion in 2019 and is expected to remain dominant during the forecast period. The growth in the region is attributed to the presence of key manufacturers in the region. The increasing awareness regarding vaccination along with secure government policies for healthcare will further support expansion in the region. Asia Pacific is expected to witness a rapid growth rate during the forecast period due to the increasing population in India and China. The growing demand for vaccines will have a positive effect on the market. Europe is expected to account for a significant share owing to the increasing demand for immunization. The prevalence of chronic diseases will spur opportunities for the market in the region.


List of the Companies Operating in the Market:

  • GlaxoSmithKline plc. (Brentford, United Kingdom)
  • Sanofi (Paris, France)
  • Pfizer Inc.  (New York, United States)
  • Merck & Co., Inc. (New Jersey, United States)
  • Novartis AG (Basel, Switzerland)
  • Emergent BioSolutions, Inc. (Maryland, United States)
  • CSL Limited (Melbourne, Australia)
  • Inovio Pharmaceuticals, Inc. (Pennsylvania, United States)
  • Bavarian Nordic (Denmark)
  • Mitsubishi Tanabe Pharma Corporation (Osaka, Japan)
  • Other Prominent Players


Have Any Query? Ask Our Experts: https://www.fortunebusinessinsights.com/enquiry/speak-to-analyst/vaccines-market-101769


Global Vaccines Market Segmentation:

By Type:

  • Recombinant/Conjugate/Subunit
  • Inactivated
  • Live Attenuated
  • Toxoid

By Route of Administration:

  • Parenteral
  • Oral

By Disease Indication:

  • Viral Diseases (Hepatitis, Influenza, Rotavirus)
  • Bacterial Diseases

By Age Group:

  • Pediatric
  • Adults

By Distribution Channel:

  • Hospital
  • Retail Pharmacies

By Geography:

  • North America (USA, Canada)
  • Europe (UK, Germany, France, Italy, Spain, Scandinavia and Rest of Europe)
  • Asia Pacific (Japan, China, India, Australia, Southeast Asia and Rest of Asia Pacific)
  • Latin America (Brazil, Mexico, Rest of Latin America)
  • Middle East & Africa (South Africa, GCC, and Rest of Middle East & Africa)


Get your Customized Research Report: https://www.fortunebusinessinsights.com/enquiry/customization/vaccines-market-101769


Table of Contents:

1. Introduction
1.1. Research Scope
1.2. Market Segmentation
1.3. Research Methodology
1.4. Definitions and Assumptions
2. Executive Summary
3. Market Dynamics
3.1. Market Drivers
3.2. Market Restraints
3.3. Market Opportunities
4. Key Insights
4.1 Key Industry Developments – Merger, Acquisitions, and Partnerships
4.2 Technological Developments
4.3 Porter’s Five Forces Analysis
4.4 SWOT Analysis
4.5 Impact of COVID-19
5. Global Vaccines Market Analysis, Insights and Forecast, 2017-2027
5.1. Key Findings / Summary
Continued….


About Us:

Fortune Business Insights™ offers expert corporate analysis and accurate data, helping organizations of all sizes make timely decisions. We tailor innovative solutions for our clients, assisting them to address challenges distinct to their businesses. Our goal is to empower our clients with holistic market intelligence, giving a granular overview of the market they are operating in.

Contact Us:

Fortune Business Insights™ Pvt. Ltd.
308, Supreme Headquarters,
Survey No. 36, Baner,
Pune-Bangalore Highway,
Pune – 411045, Maharashtra, India.


Phone:
US :+1 424 253 0390
UK : +44 2071 939123
APAC : +91 744 740 1245
Email: sales@fortunebusinessinsights.com
Fortune Business Insights™
LinkedIn | Twitter | Blogs

Disclaimer & Cookie Notice

Welcome to GOLDEA services for Professionals

Before you continue, please confirm the following:

Professional advisers only

I am a professional adviser and would like to visit the GOLDEA CAPITAL for Professionals website.

Important Notice for Investors:

The services and products offered by Goldalea Capital Ltd. are intended exclusively for professional market participants as defined by applicable laws and regulations. This typically includes institutional investors, qualified investors, and high-net-worth individuals who have sufficient knowledge, experience, resources, and independence to assess the risks of trading on their own.

No Investment Advice:

The information, analyses, and market data provided are for general information purposes only and do not constitute individual investment advice. They should not be construed as a basis for investment decisions and do not take into account the specific investment objectives, financial situation, or individual needs of any recipient.

High Risks:

Trading in financial instruments is associated with significant risks and may result in the complete loss of the invested capital. Goldalea Capital Ltd. accepts no liability for losses incurred as a result of the use of the information provided or the execution of transactions.

Sole Responsibility:

The decision to invest or not to invest is solely the responsibility of the investor. Investors should obtain comprehensive information about the risks involved before making any investment decision and, if necessary, seek independent advice.

No Guarantees:

Goldalea Capital Ltd. makes no warranties or representations as to the accuracy, completeness, or timeliness of the information provided. Markets are subject to constant change, and past performance is not a reliable indicator of future results.

Regional Restrictions:

The services offered by Goldalea Capital Ltd. may not be available to all persons or in all countries. It is the responsibility of the investor to ensure that they are authorized to use the services offered.

Please note: This disclaimer is for general information purposes only and does not replace individual legal or tax advice.